Max Meehan is a biotechnology executive. Previously, he was a member of the investment team at Altaris Capital Partners, where he executed transactions in the biopharma industry. Max began his career in the healthcare practice at Bain & Company. In addition to the Rubin Museum, Max advises safety-net hospitals on regulatory, financial, and health policy issues. He is passionate about Himalayan art and cultures, as well as bridging art and science.
Max holds an MBA from Harvard Business School and Masters in Biotechnology from Harvard University. He also holds an AB in Chemistry and Chemical Biology from Harvard College.